Exploring the Economic Impact of Private Equity in Emerging Industries – An Analysis of the Dutch Life Sciences Sector
AbstractThe aim of this paper is to discuss the competitive effects of the private equity industry in emerging industries, with a focus on the Dutch Life Sciences cluster located in West Holland, a Dutch region. As this analysis shows, the circumstances which favored the early success of this industry include factors such as education, infrastructure, governmental support, the existence of key industrial players, as well as the investment strategies of private actors. What this paper underline is the significant influence of private equity investments for the financial support of innovative products, on one side, and the growing opportunities through, on the other side. The paper is structured in two parts. The first reviews the literature regarding the evolution of emerging industries and the impact of geographic locations on their attractiveness to private investors. The second part highlights the way in which an emerging industry (i.e. life sciences industry in West Holland region) has upgraded its competitive advantage under the influence of private capital.
BiotechGate Database (2018). Life science trend analysis. Retrieved from www.biotechgate.com/web/cms/index.php/life_science_trend_analysis.html.
British Bankers' Association (2014). Financing European Growth. Retrieved from https://www.bba.org.uk/.
Chesbrough, H.W. (2002). Making sense of corporate venture capital. Harvard Business Review, 80(3), 90-99.
Delgado, M., Porter, M.E., and Stern, S. (2016). Clusters and the great recession. Retrieved from http://mitsloan.mit.edu/shared/ods/documents/?DocumentID=4075.
Ernst & Young (2012). Globalizing Venture Capital. Retrieved from https://www.ey.com/Publication/vwLUAssets/Globalizing_venture_capital_VC_insights_and_trends_report_CY0227/$FILE/Globalizing%20venture%20capital_VC%20insights%20and%20trends%20report_CY0227.pdf
Ernst & Young (2016). Beyond borders 2016: Biotech financing. Retrieved from https://www.ey.com/gl/en/industries/life-sciences/ey-vital-signs-beyond-borders-2016-biotech-financing.
European Cluster Observatory (2012). Emerging industries report on the methodology for their classification and on the most active, significant and relevant new emerging industrial sectors. Retrieved from http://ec.europa.eu/growth/industry/policy/cluster/observatory_en.
European Cluster Observatory (2016). European Cluster Panorama 2016. Retrieved from http://ec.europa.eu/growth/industry/policy/cluster/observatory_en.
European Commission (2002). Life sciences and biotechnology - A strategy for Europe. Communication from the Commission to the European Parliament, the Council, the Economic and Social Committee and the Committee of the Regions. Brussels: European Commission.
European Commission (2016). European Regional Competitiveness Index. Retrieved from https://ec.europa.eu/regional_policy/en/information/maps/regional_competitiveness/.
European Investment Bank (2018). Access-to-finance conditions for Life Sciences R&D. Retrieved from http://www.eib.org/en/infocentre/publications/all/access-to-finance-for-life-sciences-rd.htm.
European Investment Fund (2017). Financing Micro Firms in Europe: An Empirical Analysis. Luxembourg: European Investment Fund.
European Investment Fund (2018). European Small Business Finance Outlook: December 2017. Luxembourg: European Investment Fund.
European Savings and Retail Banking Group (2016). Financial systems in Europe and the United States: Structural differences where banks remain the main source of finance for companies. Bruxelles: E.S.B.G
European Venture Capital Association (2007). Guide on Private Equity and Venture Capital for Entrepreneurs. Retrieved from https://www.investeurope.eu/media/78722/guide-on-private-equity-and-venture-capital-2007.pdf.
Forbes, D.P., and Kirsch, D.A. (2011). The study of emerging industries: Recognizing and responding to some central problems. Journal of Business Venturing, 26(5), 589-602.
Frontier Economics (2013). Exploring the impact of private equity on economic growth in Europe. A report prepared for the EVCA. London: Frontier Economics.
Gilligan, J., and Wright, M. (2010). Private equity demystified: An explanatory guide. London: Corporate Finance Faculty
Health Consumer Powerhouse (2017). Euro Health Consumer Index 2017. Retrieved from https://healthpowerhouse.com/publications/euro-health-consumer-index-2017/.
InterCluster (2010). White paper: the emerging of European world-class clusters. Retrieved from https://en.calameo.com/read/000247397ad80d9a0b27a?authid=Qpz1lGMJQnjC.
Invest Europe (2017). The acceleration point: Why now is the time for European Venture Capital. Retrieved from https://www.investeurope.eu/media/664430/InvestEurope_Acceleration-Point_VCReport_05072017.pdf.
Invest Europe (2018). European Data Cooperative. Retrieved from https://www.investeurope.eu/data.
Kaplan, S.N., and Stromberg, P. (2009). Leveraged buyouts and private equity. Journal of Economic Perspectives, 23(1), 121-146.
KPMG (2018). Site Selection for Life Sciences Companies in Europe. Retrieved from https://assets.kpmg.com/content/dam/kpmg/ch/pdf/site-selection-for-life-sciences-companies-europe-2018-en.pdf.
Marshall, A. (1980). The Principles of Economics. Hampshire: McMillan.
Mihuzo Bank (2013). Life Sciences and Biotechnology Industry Clusters in Europe - Building Bridges between Science and Industry. Retrieved from https://www.mizuhobank.com/fin_info/industry/pdf/mif_122.pdf.
Mihuzo Bank (2014), Life Sciences and Biotechnology Industry Clusters in Europe- Recent Trends and Partnership Strategies for Growth and Expansion. Retrieved from https://www.mizuhobank.com/fin_info/industry/pdf/mif_147.pdf.
Netherlands Foreign Investment Agency (2018). Key Industries. Retrieved from https://investinholland.com/.
OECD (2018). Gross domestic spending on R&D (indicator). Retrieved from https://data.oecd.org/rd/gross-domestic-spending-on-r-d.htm.
PharmInvestHolland (2018). The Netherlands – Europe’s most attractive and innovative biopharmaceutical industry environment. Retrieved from https://www.health-holland.com/news/2018/03/the-netherlands-europe-s-most-attractive-and-innovative-biopharmaceutical-industry-environment.
Popov, A., and Roosenboom, P. (2009). On the real effects of private equity investment: Evidence from new business creation. Frankfurt: European Central Bank.
Porter, M.E. (1990). The competitive advantage of nations. Competitive Intelligence Review, 1(1), 14-14.
Porter, M.E. (1998). Clusters and the new economics of competition. Harvard Business Review, 76(6), 77-90.
Porter, M.E. (2000). Location, competition, and economic development: Local clusters in a global economy. Economic development quarterly, 14(1), 15-34.
Price Waterhouse Coopers (2017). Doing Business in the Netherlands. Retrieved from https://www.pwc.nl/en/publicaties/doing-business-in-the-Netherlands-2017.html.
Russo, M.V. (2003). The emergence of sustainable industries: building on natural capital. Strategic Management Journal, 24(4), 317-331.
Schumpeter, J.A. (1939). Business Cycles. A Theoretical, Historical and Statistical Analysis of the Capitalist Process. London: McGraw-Hill.
Science Business (2016). Leading Life Sciences Clusters in Europe Report. Retrieved from https://sciencebusiness.net/report/leading-life-sciences-clusters-europe.
Seretakis, A. (2012). A comparative examination of private equity in the United States and Europe: Accounting for the past and predicting the future of European private equity. Fordham Journal of Corporate & Financial Law, 18, 613-667.
Van de Bovenkamp, H.M., and Trappenburg, M.J. (2011). Government Influence on Patient Organizations. Health Care Analysis, 19(4), 329–351.
World Economic Forum (2018). Global Competitiveness Index 2017-2018. Geneva: World Economic Forum.
World Health Organization (2005). Life science research: opportunities and risks for public health. Mapping the issues. Retrieved from http://www.who.int/ethics/Life%20Science%20Research.pdf.
How to Cite
Under the Creative Commons Attribution-NonCommercial-NoDerivs license, the users are free to share (copy, distribute and transmit the contribution) with the condition to attribute the contribution in the manner specified by the author or licensor. They may not alter, transform, or build upon this work.